×
About 16,618 results

Non–Clear Cell Renal Cell Carcinoma: A Conversation About Subtypes, Clinical Trials, Treatment Options, and Outcomes
https://www.medscape.com/viewarticle/968741

Oct 4th, 2022 - This transcript has been edited for clarity. Sumanta Pal, MD: Hi. My name is Dr Monty Pal. I'm a medical oncologist at the City of Hope Comprehensive Cancer Center. I'm here today for Medscape's InDiscussion series on renal cell carcinoma. We've done several of these, and today we're going to be tackling a topic that is very near and dear to my heart, and that's non–clear cell kidney cancer. I'...

Could Your Patients Benefit? New Trials in Noncolorectal GI Cancer
https://www.medscape.com/viewarticle/981650

Sep 29th, 2022 - Several new studies in noncolorectal GI cancers have launched in recent months. Could one of your patients benefit from participating? Advanced hepatocellular cancer after at least two previous systemic therapies. Adult patients meeting this clinical scenario for whom there are no curative treatment options can join a randomized, blinded, phase 2 study testing the effectiveness of a radio wave ...

Neoadjuvant Immunotherapy Shows Promise for Resectable CSCC
https://www.medscape.com/viewarticle/981530

Sep 27th, 2022 - Neoadjuvant immunotherapy for stage II-IV cutaneous squamous cell carcinoma (CSCC) led to a strong pathological complete response rate, according to results from a stage 2 clinical trial. CSCC hasn't received much attention from pharmaceutical companies, in part because it so often responds well to surgery or local therapy. Still, some patients develop more advanced cancer that requires surgery...

Allergists Seek to Bolster Adherence to Shots, Sublingual Drops Treatments
https://www.medscape.com/viewarticle/981383

Sep 26th, 2022 - Two new studies highlight the challenges for patients in sticking with allergy shots or sublingual immunotherapy. Both studies add to arguments in favor of having frank discussions before selecting these options and of making it easier to complete those treatments. The International Forum of Allergy and Rhinology published two studies by Sandra Lin, MD, of the University of Wisconsin and collea...

How an Expert Would Manage Her Own Advanced Gynecologic Cancer
https://www.medscape.com/viewarticle/981274

Sep 23rd, 2022 - Approximately 1.9 million Americans are diagnosed with a potentially lethal cancer each year. That number is in addition to the approximately 3 million who are diagnosed with basal and squamous cell cancers, the vast majority of whom survive. Approximately 600,000 Americans experience progression of a potentially lethal cancer to beyond standard of curative care each year. About 280,000 are fem...

AI Tool May Improve Prediction of Colorectal Cancer Recurrence
https://www.medscape.com/viewarticle/981278

Sep 22nd, 2022 - Using artificial intelligence (AI), researchers have developed an algorithm that can help improve the prediction of colorectal cancer (CRC) recurrence. The QuantCRC algorithm can identify patients with CRC who might be able to skip chemotherapy, given a low probability of recurrence, and identify those patients at high risk for recurrence who may benefit from more intensive treatment or follow-...

Atezolizumab Doubles Survival of Patients With NSCLC and Poor Performance Status
https://www.medscape.com/viewarticle/981097

Sep 20th, 2022 - PARIS — Patients with untreated non–small cell lung cancer (NSCLC) who could not withstand the rigors of platinum-based chemotherapy regimens had significantly better overall survival when treated with the immune checkpoint inhibitor atezolizumab (Tecentriq), compared with their counterparts treated with either vinorelbine or gemcitabine in a phase 3 randomized trial. Among 353 patients with tr...

Immunotherapy and Lung Cancer Treatment
https://www.medscape.com/viewarticle/969534

Sep 15th, 2022 - This transcript has been edited for clarity. Jacob Sands, MD: Hello. I'm Dr Jacob Sands, thoracic medical oncologist at Dana-Farber Cancer Institute. Welcome to Medscape's InDiscussion series on lung cancer. Today, we'll be discussing immunotherapy and lung cancer treatment. First, let me introduce my guest, Dr Jared Weiss. Dr Weiss is a professor of medicine at UNC's Lineberger Comprehensive C...

Time Toxicity: A 'Very Hidden' Cost of Cancer Care
https://www.medscape.com/viewarticle/980833

Sep 15th, 2022 - Cancer care can gobble up hours on the clock. The time spent traveling to the cancer center, as well as the time spent sitting in waiting rooms and dealing with adverse events and other problems, eat into the precious time that a cancer patient has left ― which, depending on the cancer and the stage, may not be long. The problem has been termed "time toxicity," and a growing number of oncologis...

'Magic' of Psychedelics: Easing the Trauma of Terminal Illness
https://www.medscape.com/viewarticle/980569

Sep 12th, 2022 - Something was gnawing at Manish Agrawal, MD. Every day, the oncologist treated patients with standard cancer therapies, but his care could never touch their deepest pains: their despair about death. "In 20 years, I've had close to 100,000 patient encounters," Agrawal says, "and the one thing I know we don't do well is dying." Hospitalist Shoshana Ungerleider, MD, was also troubled by the care h...

Could Nivolumab Prevent Oral Cancer in High-Risk Patients?
https://www.medscape.com/viewarticle/980577

Sep 12th, 2022 - The immune checkpoint inhibitor nivolumab (Opdivo) appears to prevent the transformation of oral proliferative leukoplakia (PL), a high-risk precancerous disease, into oral cancer, suggest the results from a phase 2 study. “We think that immunotherapy as a preventative strategy, either as first-line or even secondary prevention, should be further explored,” said lead researcher Glenn J. Hanna, ...

Cabozantinib Boosts Dual Immunotherapy in Advanced RCC
https://www.medscape.com/viewarticle/980582

Sep 12th, 2022 - PARIS — Adding cabozantinib (Cabometyx) to standard-of-care immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) markedly improved progression-free survival (PFS) in advanced renal cell carcinoma (aRCC), particularly in intermediate-risk patients, suggest results from the COSMIC-313 trial. At present, dual checkpoint inhibition with nivolumab and ipilimumab is a standard of care for f...

Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro
https://www.medscape.com/viewarticle/980547

Sep 11th, 2022 - Dr Robert J. Motzer PARIS — New disappointing results from a trial of adjuvant immunotherapy for patients with renal cell carcinoma who underwent nephrectomy contrast with those from a previous trial that showed benefit with another agent. The new results, from CheckMate 914, show that adjuvant treatment with the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) did not improve disease...

Not Just What, But When: Neoadjuvant Pembrolizumab in Melanoma
https://www.medscape.com/viewarticle/980549

Sep 11th, 2022 - Dr Sapna Patel Paris — "It's not just what you give, it's when you give it," said the investigator reporting "that the same treatment for resectable melanoma given in a different sequence can generate lower rates of melanoma recurrence." Sapna Patel, MD, associate professor of melanoma medical oncology at The University of Texas MD Anderson Cancer Center, reported the results from the SWOG S180...

'Unprecedented' Responses to Neoadjuvant Treatment in dMMR Colon Cancer
https://www.medscape.com/viewarticle/980548

Sep 11th, 2022 - Dr Myriam Chalabi PARIS — "Unprecedented" pathologic responses were seen after a neoadjuvant 4-week course of ipilimumab (Yervoy) plus nivolumab (Opdivo) was given before surgery to patients with DNA mismatch repair deficient (dMMR) colon cancer, say researchers reporting new results from the NICHE-2 trial. The trial involved 112 patients with dMMR colon cancer who were given one cycle of low-d...

Novel Cell Therapy Beats Immunotherapy in Melanoma
https://www.medscape.com/viewarticle/980543

Sep 10th, 2022 - PARIS — Cell therapies have already had a huge impact on the treatment of blood cancers, but progress in solid tumors has proved more difficult. Now, in a first multicenter randomized trial to compare the two, a novel cell therapy showed a superior outcome to immunotherapy in patients with advanced melanoma. The cell therapy used in this trial was composed of adoptive tumor infiltrating lymphoc...

New Method Promises to Yield More Therapeutic T Cells
https://www.medscape.com/viewarticle/980483

Sep 9th, 2022 - Producing the T lymphocytes that are increasingly being used to fight cancer and other diseases may soon be faster and more efficient, thanks to research being conducted at the University of British Columbia, in Vancouver, Canada. Investigators found that adding the human proteins DLL4 and VCAM1 — rather than using traditional animal products — during a key cellular transition phase enhanced do...

Key Advances in Radiation Therapy for Bladder Cancer
https://www.medscape.com/viewarticle/970414

Sep 8th, 2022 - This transcript has been edited for clarity. Cheryl Lee, MD: Welcome to Medscape InDiscussion. I'm Dr Cheryl Lee. Today, we'll be talking about radiation therapy for patients with high-risk bladder cancer. How is immunotherapy used to optimize radiation treatments for bladder cancer? What's the impact of newer technology on radiation therapy — in particular, artificial intelligence? How is this...

New Nasal Spray Approved for Nasal and Ocular Seasonal Allergic Rhinitis
https://www.medscape.com/viewarticle/980360

Sep 7th, 2022 - Patients with both nasal and ocular symptoms of seasonal allergic rhinitis (SAR) have a new treatment option that combines olopatadine hydrochloride and mometasone furoate in the form of a nasal spray. Ryaltris (Hikma Pharmaceuticals PLC and Glenmark Pharmaceuticals Ltd) is approved by the US Food and Drug Administration for adults and children aged 12 years and older and has an onset of action...

Advances in Treatment Options for Early-Stage NSCLC
https://www.medscape.com/viewarticle/975486

Sep 7th, 2022 - Julia K. Rotow, MD, outlines some major areas where advances are needed in the management of patients with early-stage non–small cell lung cancer (NSCLC). First, she anticipates that immunotherapies and targeted therapies available in the metastatic setting will become available as personalized therapy for patients in the early-stage setting. Additionally, Dr Rotow looks at tools such as cell-f...